\
&
Contact us
\
&
Contact us
Published on | 3 months ago
ProgrammesThe European Defence Fund (EDF) has published its work programme for 2026, allocating €1 billion for defence research and development projects. The programme, approved on 17 December 2025, features 31 call topics aimed at enhancing military capacities.
This includes seven thematic calls for proposals, three non-thematic calls, and one initiative focusing on threats posed by hypersonic glide vehicles.
Additionally, it encompasses two actions aimed at supporting the EU alliance for medical countermeasures in defence. This structured approach aims to foster collaboration in the defence sector and advance innovative solutions.
For further details, including the full list of call topics, indicative budget, and fact sheet, please visit the European Commission's website at EDF Work Programma 2026.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has amended the 2025-2027 Digital Europe main work programme. The amendment ("March 2026") can be found on the Commission website alongside the work programme. According to the amendment, the following call topics are part of the next round of calls: Digital solutions for regulatory compliance through data Apply AI: Pil... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
